Compare ADMA Biologics Inc (ADMA) vs Hims and Hers Health Inc (HIMS) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Hims & Hers Health trades at $38.28, up 4.02% today, showing strong momentum near its 52-week high. The stock exhibits a bullish technical trend with support at $37 and resistance at $39. Fundamentally, revenue reached $2.35 billion in 2025 with a gross margin of 71.72%, though net income turned negative in 2026. Recent news highlights growth in weight-loss subscriptions and a price target increase from Canaccord Genuity to $40 (July 1, 2026).

The outlook is mixed: bullish technicals and subscriber growth contrast with high valuation multiples (P/E 57.14) and recent earnings misses. Key risks include execution in competitive telehealth and reliance on obesity drug trends. Analysts are cautious with 65% hold ratings, consensus target $33.43 suggests limited upside from current levels.